900 Middlefield Road
4th Floor
Redwood City, CA 94063
United States
650 980 9099
https://biomeafusion.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 112
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 950.41k | N/A | 1981 |
Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | N/A | N/A | 1963 |
Mr. Franco Valle | CFO & Principal Accounting Officer | 673.66k | N/A | 1981 |
Dr. Juan Pablo Frias M.D. | Chief Medical Officer | 492.25k | N/A | N/A |
Mr. Heow Tan | Chief Technology & Quality Officer | N/A | N/A | 1959 |
Ms. Naomi Cretcher | Chief People Officer | N/A | N/A | N/A |
Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | N/A | N/A | 1970 |
Dr. Stephan Morris M.D. | Chief Development Officer | N/A | N/A | N/A |
Mr. Ravi Upasani | Executive Vice President of Intellectual Property | N/A | N/A | N/A |
Caroline Perez- Dupont | Senior Vice President of Contracts | N/A | N/A | N/A |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.